Arcus Biosciences, Inc. (RCUS)
RCUSNYSEBiotechnology: Pharmaceutical Preparations
$18.95
+0.6700 (+3.67%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.73bn
- P/E
- –
- EPS, last 4 quarters
- $-3.63
- Dividend yield
- –
- Day range
- –
- 52-week range
- $17.43 to $31.74
- Average volume
- 609.0k
- Previous close
- $18.28
Analysts
12 coveringBuy10 buy, 2 hold, 0 sell
Targets a year out average $42.25, +123.0% from here
Earnings
next estimate $-0.8800Next report
Dec 2025
+19.8%
Mar 2026
-10.9%
Jun 2026
+26.5%
Sep 2026
-8.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $33.00m | $17.00m | $41.00m | $9.00m |
| Gross profit | $33.00m | $17.00m | $41.00m | $9.00m |
| Operating income | -$114.00m | -$134.00m | -$96.00m | -$131.00m |
| Net income | -$106.00m | -$128.00m | -$91.00m | -$128.00m |
Last four quarters: revenue $100.00m, margin -453.0%, free cash flow –
News
8 latest- Arcus Biosciences, Inc. Reports Third-Quarter 2026 Financial ResultsFintel · 5 days ago
- Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- Arcus Biosciences, Inc. Closes Public Offering of 16,428,572 Shares of Common Stock for Net Proceeds of Approximately $269.7 millionFintel · Oct 23, 2026
- Arcus Biosciences Prices $250 Mln Public Offering At $17.50/Share RTTNews · Oct 22, 2026
- Arcus Biosciences, Inc. Estimates $694.0 million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2026Fintel · Oct 22, 2026
- Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Zacks · Oct 21, 2026
- Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 21, 2026
- Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor DayMarketBeat · Oct 21, 2026
The company
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases. Founded in 2015, Arcus pairs proven biology with exceptional chemistry to create medicines that deliver meaningful improvements for patients. The company has advanced two oncology programs to Phase 3 clinical trials, including casdatifan, a HIF-2 inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. Arcus is also applying its small-molecule, medicinal chemistry and antibody capabilities to expand into immunology. Every program is held to the highest standard: outperform the current standard of care.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- arcusbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.